Hamlet BioPharma AB — Investor Relations & Filings

Hamlet BioPharma AB is a pharmaceutical company developing novel treatments for cancer and infections. Its lead oncology candidate, Alpha1H, is designed to selectively target and kill tumor cells while sparing healthy tissue. Alpha1H has completed Phase II clinical trials for bladder cancer, demonstrating significant tumor reduction and the activation of an anti-tumor immune response. The company is also advancing immunotherapy as an alternative to antibiotics. A Phase II trial using the IL-1 inhibitor anakinra for recurrent acute cystitis (urinary tract infections) showed efficacy comparable to standard antibiotic treatment. Another Phase II study demonstrated that anakinra significantly reduced symptoms and improved quality of life for patients with Bladder Pain Syndrome.